| HOME >> BIOLOGY >> TECHNOLOGY |
(112,270)(109,123)(231,899)(239,665)Research and development expense
(1,544,605)(1,133,962)(2,856,484)(2,695,351)Selling, general and administrative expense
(1,230,103)(649,096)(2,280,750)(1,408,366)Total operating expense
(2,886,978)(1,892,181)(5,369,133)(4,343,382)Loss from operations(2,559,839)(1,559,940)(4,709,703)(3,650,471)Interest income
2,2285,4004,21629,847Loss before taxes
(2,557,611)(1,554,540)(4,705,487)(3,620,624)Income tax expense
----Net loss$ (2,557,611)$ (1,554,540)$ (4,705,487)$ (3,620,624)Net loss per share, basic
$
(0.15)$
(0.11)$
(0.27)$
(0.25)Net loss per share, diluted
$
(0.15)$
(0.11)$
(0.27)$
(0.25)Weighted average shares outstanding, basic
17,150,64814,357,16217,150,64814,357,162Weighted average shares outstanding, diluted
17,150,64814,357,16217,150,64814,357,162Spherix IncorporatedConsolidated Balance SheetsASSETSJune 30, 2010
(Unaudited) December 31,
2009Current assetsCash and cash equivalents
$
4,585,803$
9,026,002Short-term investments, held to maturity
125,000375,003Trade accounts receivable, net
286,102274,153Other receivables
28,886948Prepaid expenses and other assets
95,141209,255Total current assets
5,120,9329,885,361Property and equipment, net
189,964225,958Patents, net of accumulated amortization of $41,622 and $38,588
5,3308,364Deposit
35,62535,625Total assets
$
5,351,851$
,155,308LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilitiesAccounts payable and accrued expenses
$
,651,338$
,714,140Accrued salaries and benefits
396,896388,665Deferred reven
'/>"/>
| SOURCE Spherix Incorporated Copyright©2010 PR Newswire. All rights reserved |